Clinical effect of omalizumab in the treatment of moderate to severe refractory allergic asthma in children and adolescents and its influences on lung function,inflammatory factors and quality of life
Objective To analyze the clinical effect of omalizumab in the treatment of moderate to severe refractory allergic asthma in children and adolescents.Methods A total of 76 children and adolescents with moderate to severe refractory allergic asthma admitted in our hospital from March 2020 to March 2022 were selected as the research objects.According to different treatment methods,the children and adolescents were divided into control group(n=36)and study group(n=40).The control group was treated with budesonide formoterol+montelukast sodium,and the study group was treated with omalizumab on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the forced expiratory volume in one second as a percentage of the expected value(FEV1%pred),forced expiratory volume in one second/forced vital capacity(FEV1/FVC)and peak expiratory flow(PEF)in the study group were higher than those in the control group(P<0.05).After treatment,the levels of fractional exhaled nitric oxide(FeNO),eosinophils(EOS)count and total immunoglobulin E(IgE)in the study group were lower than those in the control group(P<0.05).After treatment,the asthma symptom score in the study group was lower than that of the control group,and the Pediatric Asthma Quality of Life Questionnaire(PAQLQ)score was higher than that in the control group(P<0.05).The clinical control effect in the study group was better than that in the control group(P<0.05).Conclusion Omalizumab has a significant clinical effect in the treatment of moderate to severe refractory allergic asthma in children and adolescents.It can reduce the inflammatory symptoms of the airway,improve the lung function and quality of life,and has high safety.
NETL
NSTL
万方数据
